AKR1B10 and hepatocellular carcinoma: Thus, although AKR1B10 may be a molecular marker reflecting the progression of NAFLD ranging from steatohepatitis to HCC, further clinical studies are required to standardize the measurement of plasma/serum AKR1B10.